---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-072992"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-08-01T23:59:59+00:00"
generated_at: "2026-05-17T21:47:22.301321+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocugen reports Q2 2025 results; cash $27.3M; initiates OCU410ST Phase 2/3 trial

## Summary
- Cash, cash equivalents and restricted cash $27.3M as of June 30, 2025, down from $58.8M at Dec 31, 2024; cash runway into Q1 2026.
- Net loss $0.05 per share for Q2 2025, compared to $0.06 per share in Q2 2024; total operating expenses $15.2M.
- Initiated dosing in Phase 2/3 GARDian3 trial for OCU410ST (Stargardt disease) after FDA clearance; received Rare Pediatric Disease Designation.
- Signed binding term sheet for exclusive Korean rights to OCU400 with up to $11M in upfront and milestone payments.
- Announced planned reverse merger of OrthoCellix with Carisma to spin off NeoCart, with OrthoCellix valued at $135M.

## SEC filing metadata
- accession: 0001104659-25-072992
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465925072992/0001104659-25-072992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465925072992/tm2522209d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-072992
- JSON: https://secwatch.observer/filing/0001104659-25-072992.json
- Plain text: https://secwatch.observer/filing/0001104659-25-072992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.